Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments

Reuters

2025/08/04

<a href="https://laohu8.com/S/PRAX">Praxis Precision Medicines</a> Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments

Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system $(CNS)$ disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide $(ASO.AU)$ platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556382335"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556382335\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556382335?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556382335","market":"fut","top_or_hot":-1,"title":"Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide <a href=\"https://laohu8.com/S/ASO.AU\">$(ASO.AU)$</a> platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-04 21:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide <a href=\"https://laohu8.com/S/ASO.AU\">$(ASO.AU)$</a> platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDLvGTPL:1","article_id":"2556382335","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556382335","pubTimestamp":1754313936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system  disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide  platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PRAX":"Praxis Precision Medicines, Inc."},"translate_title":"Praxis Precision Medicines推出公司演示文稿，重点介绍中枢神经系统疾病治疗的创新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":0.9},"content_text":"Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments\n    \n\n        Praxis Precision Medicines Inc. has released a corporate presentation highlighting its focus on bringing innovative treatments to patients with central nervous system $(CNS)$ disorders. The presentation outlines the company's strategic pillars, emphasizing genetics, translational tools, efficient and rigorous clinical development, and patient-guided strategies. Praxis is advancing its therapeutic pipeline with assets in late-stage development and expects clinical readouts in the next four quarters. The company operates two platforms to optimize drug development: the CEREBRUM small molecule platform and the SOLIDUS antisense oligonucleotide $(ASO.AU)$ platform. Key molecules being developed include ulixacaltamide for essential tremor, relutrigine for various epilepsies, and elsunersen for SCN2A-DEE. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}